Alexandra Mazharian, Ophélie Bertin, Amrita Sarkar, Johanna Augros, Alicia Bornert, Cécile Loubière, Friederike Jönsson, Juli Warwicker, W Mark Abbott, Omer Dushek, Caroline Vayne, Lubica Rauova, Klaus Fütterer, Jérôme Rollin, Mortimer Poncz, Yotis A Senis
Platelets are highly reactive fragments of megakaryocytes that play a fundamental role in thrombosis and hemostasis. Predictably, all conventional anti-platelet therapies elicit bleeding, raising the question whether the thrombotic activity of platelets can be targeted separately. In this study, we describe a novel approach of inhibiting platelet activation through the use of bispecific single-chain variable fragments (bi-scFvs), termed cis-acting platelet receptor inhibitors (CAPRIs) that harness the immunoreceptor tyrosine-based inhibition motif (ITIM)-containing co-inhibitory receptor G6b-B (G6B) to suppress immunoreceptor tyrosine-based (ITAM)-containing receptor-mediated platelet activation...
May 14, 2024: bioRxiv